Cyfuse Biomedical KK (FSE:4892) Other Current Assets: 円73.66 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4892 Cyfuse Biomedical KK FSE:4892
31 GF Score
Price 円527.00
GF Value 円2,172.95
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Other Current Assets?

Cyfuse Biomedical KK FSE:4892 31 Other Current Assets is 円73.66 Mil as of Dec. 2025. GuruFocus rates FSE:4892 with a GF Score™ of 31/100 and a GF Value™ of 円2,172.95. The stock has 5 warning signs investors should review.

Cyfuse Biomedical KK's other current assets for the quarter that ended in Dec. 2025 was 円73.66 Mil.

Cyfuse Biomedical KK's quarterly other current assets increased from Jun. 2025 (円45.55 Mil) to Sep. 2025 (円104.97 Mil) but then declined from Sep. 2025 (円104.97 Mil) to Dec. 2025 (円73.66Mil).

Cyfuse Biomedical KK's annual other current assets increased from Dec. 2023 (円17.79 Mil) to Dec. 2024 (円67.97 Mil) increased from Dec. 2024 (円67.97 Mil) to Dec. 2025 (円73.66 Mil).


Cyfuse Biomedical KK Other Current Assets Related Terms


Cyfuse Biomedical KK Other Current Assets Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Other Current Assets Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial 26.08 17.82 17.79 67.97 73.66

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.82 45.55 104.97 73.66 86.74
FSE:4892
31GF Score
Cyfuse Biomedical KK FSE:4892
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of 円73.66 Mil mean?
Cyfuse Biomedical KK (FSE:4892) has a Other Current Assets of 円73.66 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cyfuse Biomedical KK.
Is Cyfuse Biomedical KK's Other Current Assets too high?
Cyfuse Biomedical KK's current Other Current Assets is 円73.66 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Other Current Assets compare to ?
Cyfuse Biomedical KK's Other Current Assets of 円73.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cyfuse Biomedical KK. Cyfuse Biomedical KK's current Other Current Assets is 円73.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Cyfuse Biomedical KK (FSE:4892) has a current Other Current Assets of 円73.66 Mil. The stock's GF Value™ is 円2,172.95, compared to a current price of 円527.00 — trading 75.7% below its estimated fair value. The current Other Current Assets is 円73.66 Mil. Cyfuse Biomedical KK's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current Other Current Assets is 円73.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円527.00 is trading 75.7% below its estimated GF Value™ of 円2,172.95.

Key valuation signals for FSE:4892:

  • Other Current Assets: 円73.66 Mil
  • GF Value™: 円2,172.95 vs. price of 円527.00 (75.7% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyfuse Biomedical KK Business Description

Comparable Companies
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
31GF Score

Get the complete analysis for FSE:4892

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円527.00
Price
円2,172.95
GF Value